Researcher profile

James L. Kirkland, MD, PhD

He co-discovered the senolytic drug class in 2015 and runs the human trials testing it. When the person who found the compounds says they should not yet be taken by the public, that is the most informative sentence available on the subject.

Role
Geriatrician; co-author of the first senolytics paper
Affiliation
Mayo Clinic Kogod Center on Aging
Topics
Senolytics · Senescence · Fisetin
Their work

Why we quote Kirkland

He co-discovered the senolytic drug class in 2015 and runs the human trials testing it. When the person who found the compounds says they should not yet be taken by the public, that is the most informative sentence available on the subject.

James L. Kirkland, MD, PhD is one of the researchers quoted here; the others quoted alongside James are listed with the same disclosures.

Where they stand, and who pays

Academic, and openly gives the trials he is running roughly even odds.

Stating this next to the quote rather than at the bottom of a disclosures page is the whole point. A concession made against a commercial interest is stronger evidence than a neutral summary; a claim made in line with one is weaker. You cannot weigh either without knowing which you are reading.

Every line below is transcribed from a public recording and linked back to it. Nothing here is paraphrased, and Kirkland has no relationship with this site.

Everything we quote them saying

All 2 lines, verbatim, in the order they appear in the site's citation index. Each one links to the recording and to the page it is used on.

There are no completely sensitive and specific markers for senescent cells.

James L. Kirkland, MD, PhD(profile) Director, Kogod Center on Aging, Mayo Clinic, co-author of the first senolytics paper Foresight Institute, 2021

Used on Senolytic Dosage: Where the Intermittent Protocols Came From

You'd have to eat 15 pounds of strawberries in five minutes to get the kind of dose we're giving.

James L. Kirkland, MD, PhD(profile) Professor of Aging Research, Mayo Clinic Foresight Institute, 2021

Used on Senolytics: What Fisetin and Quercetin Have Actually Shown

Pages this research informs

Each page below cites this researcher directly, so you can see the claim a quote supports in its full context.

The standing disclaimer

James L. Kirkland, MD, PhD has no relationship with Rapamycin.store and does not endorse anything on it.

  • They have not reviewed this site or any page that quotes them.
  • Quotes are used under fair dealing for criticism and review, each linked to its public recording so you can hear the full context.
  • If a quote here misrepresents what was said, tell us and we will correct it. That correction goes to the front of the queue.

Researchers who want to set out a position in their own words, rather than be quoted, can send the editors a pitch.

References

3 sources, all link-checked; oldest check

  1. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. International Committee of Medical Journal Editors, updated 2025.The conflict-of-interest and authorship conventions this desk follows for a lay publication.Verified Sep 14, 2026
  2. PubMed. US National Library of Medicine, National Institutes of Health.The index every citation on this site is checked against before publication.Verified Sep 14, 2026
  3. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Guyatt GH et al. BMJ 2008;336:924.The framework behind the strong / mixed / limited evidence grades used across this site.Verified Sep 14, 2026

Every link above is re-requested on a schedule by an automated checker; the date shown is when it last answered. Publishers that block automated requests are marked as such rather than reported broken. Our editorial standards explain how a source gets cited here in the first place.

Filed by the Rapamycin.store evidence desk. Each source is re-checked when the page is reviewed.

Own a longevity or health brand?

Rapamycin.store publishes sponsored and guest posts on an aged, topically-relevant domain, and offers display advertising. Tell us what you want to promote and we'll send our current options.